Abnova Taiwan Corp (4133) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abnova Taiwan Corp (4133) has a cash flow conversion efficiency ratio of 0.010x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$12.73 Million ≈ $400.97K USD) by net assets (NT$1.26 Billion ≈ $39.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Abnova Taiwan Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Abnova Taiwan Corp - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Abnova Taiwan Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Abnova Taiwan Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abnova Taiwan Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Matahari Putra Prima Tbk
JK:MPPA
|
0.112x |
|
BJC Heavy Industries Public Company Limited
BK:BJCHI
|
0.054x |
|
BG Staffing Inc
NYSE:BGSF
|
0.042x |
|
Insung Information Co. Ltd
KQ:033230
|
-0.098x |
|
FOODWELL Co. Ltd
KQ:005670
|
0.092x |
|
Globetronics Tech Bhd
KLSE:7022
|
-0.016x |
|
ALANDEQGRP FPO
AU:AEG
|
-1.327x |
|
Phunware Inc
NASDAQ:PHUN
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Abnova Taiwan Corp (2009–2025)
The table below shows the annual cash flow conversion efficiency of Abnova Taiwan Corp from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Abnova Taiwan Corp (4133) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.26 Billion ≈ $39.59 Million |
NT$-4.19 Million ≈ $-132.07K |
-0.003x | -108.59% |
| 2024-12-31 | NT$1.31 Billion ≈ $41.25 Million |
NT$50.85 Million ≈ $1.60 Million |
0.039x | -34.46% |
| 2023-12-31 | NT$1.29 Billion ≈ $40.53 Million |
NT$76.22 Million ≈ $2.40 Million |
0.059x | -42.17% |
| 2022-12-31 | NT$1.29 Billion ≈ $40.70 Million |
NT$132.37 Million ≈ $4.17 Million |
0.102x | +33.67% |
| 2021-12-31 | NT$1.21 Billion ≈ $38.18 Million |
NT$92.88 Million ≈ $2.93 Million |
0.077x | -11.85% |
| 2020-12-31 | NT$1.21 Billion ≈ $38.16 Million |
NT$105.30 Million ≈ $3.32 Million |
0.087x | +39.14% |
| 2019-12-31 | NT$1.19 Billion ≈ $37.57 Million |
NT$74.51 Million ≈ $2.35 Million |
0.062x | -13.99% |
| 2018-12-31 | NT$1.23 Billion ≈ $38.66 Million |
NT$89.17 Million ≈ $2.81 Million |
0.073x | +31.77% |
| 2017-12-31 | NT$1.22 Billion ≈ $38.59 Million |
NT$67.53 Million ≈ $2.13 Million |
0.055x | -9.84% |
| 2016-12-31 | NT$1.18 Billion ≈ $37.06 Million |
NT$71.94 Million ≈ $2.27 Million |
0.061x | -2.83% |
| 2015-12-31 | NT$1.17 Billion ≈ $36.76 Million |
NT$73.43 Million ≈ $2.31 Million |
0.063x | -17.82% |
| 2014-12-31 | NT$1.23 Billion ≈ $38.74 Million |
NT$94.18 Million ≈ $2.97 Million |
0.077x | -14.21% |
| 2013-12-31 | NT$1.23 Billion ≈ $38.74 Million |
NT$109.78 Million ≈ $3.46 Million |
0.089x | +44.31% |
| 2012-12-31 | NT$1.23 Billion ≈ $38.72 Million |
NT$76.02 Million ≈ $2.40 Million |
0.062x | -41.44% |
| 2011-12-31 | NT$1.27 Billion ≈ $40.03 Million |
NT$134.22 Million ≈ $4.23 Million |
0.106x | +17.26% |
| 2010-12-31 | NT$1.27 Billion ≈ $40.01 Million |
NT$114.40 Million ≈ $3.60 Million |
0.090x | +71.09% |
| 2009-12-31 | NT$1.21 Billion ≈ $38.13 Million |
NT$63.72 Million ≈ $2.01 Million |
0.053x | -- |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more